114 related articles for article (PubMed ID: 12805677)
21. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10.
Steidler L; Neirynck S; Huyghebaert N; Snoeck V; Vermeire A; Goddeeris B; Cox E; Remon JP; Remaut E
Nat Biotechnol; 2003 Jul; 21(7):785-9. PubMed ID: 12808464
[TBL] [Abstract][Full Text] [Related]
22. Intracellular accumulation of trehalose protects Lactococcus lactis from freeze-drying damage and bile toxicity and increases gastric acid resistance.
Termont S; Vandenbroucke K; Iserentant D; Neirynck S; Steidler L; Remaut E; Rottiers P
Appl Environ Microbiol; 2006 Dec; 72(12):7694-700. PubMed ID: 17028239
[TBL] [Abstract][Full Text] [Related]
23. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces.
Benbouziane B; Ribelles P; Aubry C; Martin R; Kharrat P; Riazi A; Langella P; Bermúdez-Humarán LG
J Biotechnol; 2013 Oct; 168(2):120-9. PubMed ID: 23664884
[TBL] [Abstract][Full Text] [Related]
24. Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects.
Papa A; Scaldaferri F; Danese S; Guglielmo S; Roberto I; Bonizzi M; Mocci G; Felice C; Ricci C; Andrisani G; Fedeli G; Gasbarrini G; Gasbarrini A
Dig Dis; 2008; 26(2):149-55. PubMed ID: 18431065
[TBL] [Abstract][Full Text] [Related]
25. Diagnosing and managing inflammatory bowel disease.
Assadsangabi A; Lobo AJ
Practitioner; 2013; 257(1763):13-8, 2. PubMed ID: 24191430
[TBL] [Abstract][Full Text] [Related]
26. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
27. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
28. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the anti-inflammatory effect of milk fermented by a strain of IL-10-producing Lactococcus lactis using a murine model of Crohn's disease.
del Carmen S; de Moreno de LeBlanc A; Perdigon G; Bastos Pereira V; Miyoshi A; Azevedo V; LeBlanc JG
J Mol Microbiol Biotechnol; 2011; 21(3-4):138-46. PubMed ID: 22286041
[TBL] [Abstract][Full Text] [Related]
30. Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease.
Sawada K
Transfus Apher Sci; 2017 Oct; 56(5):689-697. PubMed ID: 28986009
[TBL] [Abstract][Full Text] [Related]
31. Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model.
Del Carmen S; de Moreno de LeBlanc A; Levit R; Azevedo V; Langella P; Bermúdez-Humarán LG; LeBlanc JG
Int Immunopharmacol; 2017 Jan; 42():122-129. PubMed ID: 27912148
[TBL] [Abstract][Full Text] [Related]
32. Steroid therapy for inflammatory bowel disease.
Saruta M
Nihon Rinsho; 2017 Mar; 75(3):398-402. PubMed ID: 30566781
[TBL] [Abstract][Full Text] [Related]
33. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
[TBL] [Abstract][Full Text] [Related]
34. Inflammatory bowel disease in Iran: a review of 457 cases.
Aghazadeh R; Zali MR; Bahari A; Amin K; Ghahghaie F; Firouzi F
J Gastroenterol Hepatol; 2005 Nov; 20(11):1691-5. PubMed ID: 16246187
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory bowel disease in Thai children: presentations and outcomes of treatment.
Treepongkaruna S; Pienvichit P; Sornmayura P; Pornkul R; Wisedopas N; Phuapradit P
Asian Pac J Allergy Immunol; 2006 Mar; 24(1):73-9. PubMed ID: 16913191
[TBL] [Abstract][Full Text] [Related]
36. Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice.
Shigemori S; Watanabe T; Kudoh K; Ihara M; Nigar S; Yamamoto Y; Suda Y; Sato T; Kitazawa H; Shimosato T
Microb Cell Fact; 2015 Nov; 14():189. PubMed ID: 26608030
[TBL] [Abstract][Full Text] [Related]
37. IL-10 and IL-10 receptor defects in humans.
Glocker EO; Kotlarz D; Klein C; Shah N; Grimbacher B
Ann N Y Acad Sci; 2011 Dec; 1246():102-7. PubMed ID: 22236434
[TBL] [Abstract][Full Text] [Related]
38. Wip 1 inhibits intestinal inflammation in inflammatory bowel disease.
Zhang Q; Zhang C; Chang F; Liang K; Yin X; Li X; Zhao K; Niu Q; Tian Z
Cell Immunol; 2016 Dec; 310():63-70. PubMed ID: 27687530
[TBL] [Abstract][Full Text] [Related]
39. Oral manifestations of inflammatory bowel disease: a review based on the observation of six cases.
Lourenço SV; Hussein TP; Bologna SB; Sipahi AM; Nico MM
J Eur Acad Dermatol Venereol; 2010 Feb; 24(2):204-7. PubMed ID: 19552719
[TBL] [Abstract][Full Text] [Related]
40. Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model.
del Carmen S; Martín Rosique R; Saraiva T; Zurita-Turk M; Miyoshi A; Azevedo V; de Moreno de LeBlanc A; Langella P; Bermúdez-Humarán LG; LeBlanc JG
J Clin Gastroenterol; 2014; 48 Suppl 1():S12-7. PubMed ID: 25291117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
